Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Total Valuation
Immunovant has a market cap or net worth of $3.99B. The enterprise value is $2.28B.
Market Cap$3.99B
Enterprise Value$2.28B
Share Statistics
Immunovant has 175,276,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding175,276,520
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunovant’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -62.06%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-62.06%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-1.14M
Employee Count362
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunovant is ―. Immunovant’s PEG ratio is -0.14.
PE Ratio―
PS Ratio0.00
PB Ratio3.66
Price to Fair Value3.66
Price to FCF-6.88
Price to Operating Cash Flow-9.79
PEG Ratio-0.14
Income Statement
In the last 12 months, Immunovant had revenue of 0.00 and earned -413.84M in profits. Earnings per share was -2.73.
Revenue0.00
Gross Profit0.00
Operating Income-438.15M
Pretax Income-412.95M
Net Income-413.84M
EBITDA-437.77M
Earnings Per Share (EPS)-2.73
Cash Flow
In the last 12 months, operating cash flow was -430.95M and capital expenditures -381.00K, giving a free cash flow of -431.33M billion.
Operating Cash Flow-430.95M
Free Cash Flow-431.33M
Free Cash Flow per Share-2.46
Dividends & Yields
Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-20.37%
50-Day Moving Average20.48
200-Day Moving Average17.41
Relative Strength Index (RSI)51.70
Average Volume (3m)1.69M
Important Dates
Immunovant upcoming earnings date is Feb 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateFeb 18, 2026
Ex-Dividend Date―
Financial Position
Immunovant as a current ratio of 11.16, with Debt / Equity ratio of 0.00%
Current Ratio11.16
Quick Ratio11.16
Debt to Market Cap0.00
Net Debt to EBITDA1.63
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunovant has paid 891.00K in taxes.
Income Tax891.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunovant EV to EBITDA ratio is -4.29, with an EV/FCF ratio of -4.98.
EV to Sales0.00
EV to EBITDA-4.29
EV to Free Cash Flow-4.98
EV to Operating Cash Flow-4.99
Balance Sheet
Immunovant has $521.87M in cash and marketable securities with $0.00 in debt, giving a net cash position of $521.87M billion.
Cash & Marketable Securities$521.87M
Total Debt$0.00
Net Cash$521.87M
Net Cash Per Share$2.98
Tangible Book Value Per Share$4.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunovant is $37.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.86
Price Target Upside71.93% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-27.70%